-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
According to data from Intranet, in 2021, the TOP5 terminal anti-inflammatory drugs and anti-rheumatic drugs in China's urban public hospitals, county-level public hospitals, urban community centers and township health centers (referred to as China's public medical institutions) were ketorolac tromethamine, loxoprofen, glucosamine, parecoxib and diclofenac sodium
, respectively.
Among them, ketorolac tromethamine ranks first with sales of more than 2 billion yuan, and it is also the highest growth variety
in TOP5.
Top 5 varieties of anti-inflammatory drugs and anti-rheumatic drugs in 2021 (100 million yuan)
(Source: Intranet China's public medical institution terminal competition pattern)
Ketorolac tromethamine
Ketorolac tromethamine Ketorolac tromethamine is a nonsteroidal anti-inflammatory agent commonly used for most pain relief
.
It is suitable for short-term elimination of trauma and postoperative pain, swelling pain, severe pain and pain
caused by various causes.
Tablets or injections can be used to relieve moderate to severe postoperative pain, including abdominal, chest, gynaecological , oral, orthopedic and urological procedures
.
In addition, it can also relieve acute renal colic, biliary colic, toothache, trauma pain, trigeminal neuralgia, cancer visceral pain, and all previous pain conditions
that required morphine or pethidine to take effect.
At present, the best-selling dosage form of this variety is injection, accounting for more than 90%, and Chengdu Beite Pharmaceutical is a leader in ketorolac tromethamine injection
.
In 2021, the market share of ketorolac tromethamine injection of Chengdu Beite Pharmaceutical was 43.
88%, and the market share exceeded 60%
in the first quarter of 2022.
88%, and the market share will exceed 60%
in the first quarter of 2022.
Sales of ketorolac tromethamine injection (10,000 yuan)
(Source: Intranet China's public medical institution terminal competition pattern)
Loxoprofen
Loxoprofen Loxoprofen sodium is a non-steroidal anti-inflammatory drug, mainly used for rheumatoid arthritis, osteoarthritis, low back pain, frozen shoulder, neck shoulder and wrist syndrome, as well as analgesic and anti-inflammatory after surgery, trauma and tooth extraction, antipyretic and analgesic
for acute upper respiratory tract inflammation.
The best-selling variety is Hunan Jiudian Pharmaceutical's Loxoprofen Sodium Gel Patch, Hunan Jiudian Pharmaceutical's Loxoprofen Sodium Gel Paste is the first imitation + domestic exclusive, the product only has 6 million yuan in sales in 2018, and has exceeded 800 million yuan in 2021, accounting for half of the sales of this variety
.
Glucosamine
Glucosamine Glucosamine is a kind of bone injury drug, mainly used for primary and secondary osteoarthritis, can relieve and eliminate the pain, swelling and other symptoms of osteoarthritis, improve joint mobility, and prevent the development of
osteoarthritis course.
It is reported that glucosamine used to be a large variety with terminal sales of more than 3 billion yuan in China's public medical institutions, and occupied the top 1 variety in the anti-inflammatory drug and anti-rheumatic drug market from 2013 to 2019
.
However, the total sales scale in 2021 fell to 1.
3 billion yuan, and the former scenery is no longer there
.
3 billion yuan in 2021
Parecoxib
Parecoxib Parecoxib is a cyclooxygenase-2 (COX-2)-specific inhibitor and is a coxib analgesic among antiarthritis drugs that can be used clinically for the treatment
of moderate or severe postoperative acute pain.
Sales in the domestic market of parecoxib grew rapidly and continued to climb
after breaking the 1 billion yuan mark in 2018.
According to the competition pattern database of chemical terminals in China's urban public hospitals, the sales of parecoxib sodium for injection from 2019 to 2021 were RMB 1.
994 billion, RMB 2.
189 billion and RMB 1.
273 billion
, respectively.
994 billion, RMB2.
189 billion and RMB1.
273 billion
, respectively.
Diclofenac sodium
Diclofenac sodium Diclofenac sodium is a non-steroidal anti-inflammatory drug with obvious analgesic, anti-inflammatory and antipyretic effects
.
The drug produces analgesic, anti-inflammatory, antipyretic effects
by inhibiting the synthesis of prostaglandins.
Therefore, it is one of the typical representative drugs of anti-inflammatory and analgesic drugs, mainly suitable for acute and chronic arthritis, acute and chronic ankylosing spondylitis, frozen shoulder, bursitis, tendonitis and tenosynovitis, low back pain, sprains, strains and other soft tissue injuries; Acute gout, dysmenorrhea or adnexitis, toothache and postoperative pain, etc
.
According to PDB comprehensive drug database data, in 2018, diclofenac sales worldwide were $5.
05 billion
.
According to data from Intranet, the terminal sales of diclofenac sodium in China's public medical institutions exceeded 1.
2 billion yuan
in 2021.
05 billion
.
In 2021, the terminal sales of diclofenac sodium in public medical institutions in China exceeded 1.
2 billion yuan
.
